Safety of formoterol in patients with asthma: Combined analysis of data from double-blind, randomized controlled trials

Journal of Allergy and Clinical Immunology

Volumn 125, Issue 2, 2010, Pages

  Nelson, Harold ^a   Bonuccelli, Catherine ^b   Radner, Finn ^c   Ottosson, Anders ^c   Carroll, Kevin J ^b   Andersson, Tomas L G ^c   LaForce, Craig ^d  

^a DEPARTMENT OF MEDICINE   (United States)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; formoterol; inhaled corticosteroid; safety; serious adverse events

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; PLACEBO; TERBUTALINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CAUSE OF DEATH; CHILD; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; INTUBATION; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; METERED DOSE INHALER; OUTCOME ASSESSMENT; PARALLEL DESIGN; POWDER INHALER; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCHOOL CHILD;

EID: 75849142220     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2009.11.036     Document Type: Article

References (27)

1. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program expert panel report 3: guidelines for the diagnosis and management of asthma. Full report 2007. Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm. Accessed January 27, 2009.
2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Updated 2008. Available at: http://www.ginasthma.com/Guidelineitem.asp??l1=2&l2=1&intId=60. Accessed February 5, 2009.
3. Noonan M., Rosenwasser L.J., Martin P., O'Brien C.D., and O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs 66 (2006) 2235-2254
4. Pauwels R.A., Löfdahl C.G., Postma D.S., Tattersfield A.E., O'Byrne P., et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 337 (1997) 1405-1411
5. Peters S.P., Prenner B.M., Mezzanotte W.S., Martin P., and O'Brien C.D. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc 29 (2008) 499-516
6. O'Byrne P.M., Barnes P.J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164 (2001) 1392-1397
7. Lalloo U.G., Malolepszy J., Kozma D., Krofta K., Ankerst J., Johansen B., et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroids in adults with mild-to-moderate moderate asthma. Chest 123 (2003) 1480-1487
8. Zetterström O., Buhl R., Mellem H., Perpiñá M., Hedman J., O'Neill S., et al. Improved asthma control with budesonide/formoterol in a single inhaled, compared with budesonide alone. Eur Respir J 18 (2001) 262-268
9. Corren J., Korenblat P.E., Miller C.J., O'Brien C.D., and Mezzanotte W.S. Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma. Clin Ther 29 (2007) 823-843
10. Murphy K., Nelson H., Parasuraman B., Boggs R., Miller C., and O'Dowd L. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin 24 (2008) 879-894
11. Chervinsky P., Baker J., Bensch G., Parasuraman B., Boggs R., Martin P., et al. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol 101 (2008) 463-473
12. Kerwin E.M., Oppenheimer J.J., LaForce C., Parasuraman B., Miller C.J., O'Dowd L., et al. Efficacy and tolerability of once-daily budesonide/formoterol pressurized metered-dose inhaler in adults and adolescents with asthma previously stable with twice-daily budesonide/formoterol dosing. Ann Allergy Asthma Immunol 103 (2009) 62-72
13. Nelson H.S., Carr W., Nathan R., and Portnoy J.M. Update on the safety of long-acting β-agonists in combination with inhaled corticosteroids for the treatment of asthma. Ann Allergy Asthma Immunol 102 (2009) 11-15
14. Nelson H.S., Weiss S.T., Bleecker E.R., Yancey S.W., and Dorinsky P.M. SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129 (2006) 15-26
15. Castle W., Fuller R., Hall J., and Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ 306 (1993) 1034-1037
16. Mann M., Chowdhury B., Sullivan E., Nicklas R., Anthracite R., and Meyer R.J. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest 124 (2003) 70-74
17. Bensch G., Berger W.E., Blokhin B.M., Socolovsky A.L., Thomson M.H., Till M.D., et al. International Study Group on Foradil Evaluation in Pediatric Asthma. One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma. Ann Allergy Asthma Immunol 89 (2002) 180-190
18. United States Department of Health and Human Services, Food and Drug Administration. Public health advisory. November 2005. Available at: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm162678.htm. Accessed January 27, 2009.
19. Sears M.R., Ottosson A., Radner F., and Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J 33 (2009) 21-32
20. Levenson M. Long-acting beta-agonists and adverse asthma events meta-analysis: statistical briefing package for joint meeting of the Pulmonary-Allergy Drugs Advisory Committee, Drug Safety and Risk Management Advisory Committee, and Pediatric Advisory Committee on December 10-11, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-01-FDA.pdf. Accessed April 20, 2009.
21. Kramer J.M. Balancing the benefits and risks of inhaled long-acting beta-agonists-the influence of values. N Engl J Med 360 (2009) 1592-1595
22. Barker L., and Cadwell B.L. An analysis of eight 95 per cent confidence intervals for a ratio of Poisson parameters when events are rare. Stat Med 27 (2008) 4030-4037
23. Cates C.J., Cates M.J., and Lasserson T.J. Regular treatment with formoterol for chronic asthma: serious adverse events. Cochrane Database Syst Rev 4 (2008) CD006923
24. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: statistical principles for clinical trials. Report E9. 1998. Available at: http://www.ich.org/LOB/media/MEDIA485.pdf.
25. Bisgaard H., Le Roux P., Bjåmer D., Dymek A., Vermeulen J.H., and Hultquist C. Budesonide/formoterol maintenance plus reliever therapy: a new strategy in pediatric asthma. Chest 130 (2006) 1733-1743
26. GlaxoSmithKline. Overview of asthma and guidelines for the diagnosis and management of asthma. Prepared for the United States Food and Drug Administration. Joint meeting of Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee on December 10-11, 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/slides/2008-4398s1-09-GSK.pdf. Accessed January 27, 2008.
27. GlaxoSmithKline briefing document: benefit risk assessment of salmeterol for the treatment of asthma in adults and children. Prepared for the United States Food and Drug Administration. Joint meeting of Pulmonary-Allergy Drugs Advisory Committee, Drug Safety & Risk Management Advisory Committee. 2008. Available at: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4398b1-04-GSK.pdf. Accessed April 7, 2009.